



















API

Generics 2025

API PRODUCT LIST

Product	Polymorphic form	CAS No.	 DMF	 CEP	 DMF	 DMF	 DMF	 DMF	 DMF	 CADIFA	
1. Acenocumarol		152-72-7	✓								
2. Acetazolamide	Form II	59-66-5	✓	✓	✓		✓	✓			✓
3. Alendronate sodium	Trihydrate	121268-17-5	✓	✓	✓	✓	✓	✓	✓	P	✓
4. Aniracetam	Monoclinic form	72432-10-1	✓								
5. Antazoline HCL		2508-72-7	✓								
6. Antazoline mesylate		3131-32-6	✓								
7. Antazoline sulfate	Unique crystal form of dihydrated salt of di-Antazoline sulfate [di-1Himidazole-2-methanamine, 4,5-dihydro-N-phenyl-N-(phenyl methyl)-, sulfate (2:1), dihydrate].	24359-81-7	✓								
8. Aripiprazole	Type I	129722-12-9	✓	✓	✓						✓
9. Aripiprazole monohydrate (non-sterile)	Monohydrate	851220-85-4	✓		✓						
10. Baclofen	anhydrous polymorphic form	1134-47-0	✓	✓	✓		✓	✓	✓	P	✓
11. Carbamazepine	Form III	298-46-4	✓	✓	✓			✓			
12. Carvedilol	Form II	72956-09-3	✓	✓	✓		✓	✓			
13. Carvedilol phosphate hemihydrate	Form I	610309-89-2	✓		✓						
14. Clemastine fumarate	Substance does not show polymorphism	14976-57-9	✓								
15. Clopamide	Polymorphic form	636-54-4	✓								
16. Disulfiram	Substance does not show polymorphism	97-77-8	✓	✓							
17. Etodolac	Crystalline racemate, none	41340-25-4	✓	✓	✓		✓	✓	✓	✓	
18. Hydrochlorothiazide	Form I	58-93-5	✓	✓	✓	✓	✓	✓	✓	P	✓
19. Ibandronate sodium	Monohydrate Form B	138926-19-9	✓	✓	✓	✓	✓	✓		P	CEP
20. ITCL Denotivir	Substance does not show polymorphism	51287-57-1	✓								
21. Lamotrigine	Anhydrous monoclinic	84057-84-1	✓	✓	✓	✓	✓	✓			
22. Molsidomine	Substance does not show polymorphism	25717-80-0	✓	✓					✓		
23. Nefopam Hydrochloride	Substance does not show polymorphism	23327-57-3	✓								✓
24. Opipramol dihydrochloride	Crystalline form	909-39-7	✓								
25. Oxcarbazepine	Form A	28721-07-5	✓		✓						
26. Pentoxifylline	Form I	6493-05-6	✓	✓	✓	✓		✓			✓
27. Phenyl salicylate	Crystalline orthorhombic form	118-55-8	✓								
28. Piracetam	Form II	7491-74-9	✓	✓						P	✓

API PRODUCT LIST

Product	Polymorphic form	CAS No.	 DMF	 CEP	 DMF	 DMF	 DMF	 DMF	 DMF	 CADIFA	
29. Risedronate sodium 2.5-hydrate	Form A	329003-65-8	✓	✓	✓		✓	✓	✓	P	✓
30. Rivaroxaban	Modification I	366789-02-8	✓	✓	✓	✓		✓	✓	✓	
31. Salicylamide	Monoclinic form with space group 12/a	65-45-2	✓								
32. Sildenafil citrate	Anhydrous Form	171599-83-0	✓	✓	✓	✓	✓		✓		
33. Sitagliptin hydrochloride	Form III	862156-92-1	✓		✓						
34. Sodium salicylate	Monoclinic form (space group P21/m)	54-21-7	✓		✓		✓				
35. Tadalafil	Form A (form I)	171596-29-5	✓	✓	✓	✓	✓			P	
36. Tolterodine tartrate	Crystalline Form I	124937-52-6	✓	✓					✓		
37. Topiramate	Orthorhombic structure	97240-79-4	✓		✓			✓			
38. Vardenafil hydrochloride	Trihydrate form	330808-88-3	✓	✓	✓	✓	✓	✓	✓		
39. Xylometazoline HCl	Substance does not show polymorphism	1218-35-5	✓	✓							
40. Zoledronic acid	Monohydrate	165800-06-6	✓	✓	✓		✓		✓	P	✓

P- pending

DISCLAIMER









Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

HP API PRODUCT LIST

Product	Polymorphic form	CAS No.	STATUS	OEB No.	SAMPLES
1. Trametinib Dimethyl Sulfoxide	Crystalline	1187431-43-1	Under development	5	Q4 2024
2. Abemaciclib*	Form III	1231929-97-7	Under development	4	Q1 2025
3. Vismodegib	Form B	879085-55-9	Initial stage	5	Q4 2024
4. Ozanimod			Initial stage	4	2025
5. Risdiplam		1825352-65-5	Initial stage	4	tbd
6. Gilteritinib fumarate		1254053-84-3	Initial stage	4	tbd

* partnership with Egis

DEVELOPED API

	Product	Polymorphic form	CAS No.	 DMF	 CEP	 DMF	 DMF	 DMF	 DMF	 DMF	 CADIFA
1.	Apixaban	Form N-1	503612-47-3	✓		✓			✓		P
2.	Apremilast	Form B	608141-41-9	✓		✓				✓	
3.	Baricitinib	Form I	1187594-09-7	✓		✓					
4.	Brexiprazole	anhydrous form (from I)	913611-97-9	✓		✓					
5.	Dapagliflozin	Amorphous	461432-26-8	✓		✓	✓		✓	✓	P
6.	Dapagliflozin Propanediol Monohydrate	Crystalline SC-3	960404-48-2	✓	✓	✓					P
7.	Elagolix sodium	Amorphous	832720-36-2	P		P					
8.	Empagliflozin	Crystalline anhydrous	864070-44-0	✓		✓		✓	✓	✓	P
9.	Enzalutamide	Anhydrous form R1	915087-33-1			✓					
10.	Isavuconazonium sulfate	Amorphous	946075-13-4	✓		✓					
11.	Linagliptin	Form: mix A&B	668270-12-0	✓		✓		✓	✓	✓	
12.	Palbociclib*	crystal form A	571190-30-2	✓		✓					
13.	Pimavanserin tartrate	Crystalline anhydrous form C	706782-28-7	✓		✓					
14.	Sacubitril/Valsartan complex	Crystalline	936623-90-4	✓		✓					
15.	Safnamide methanesulfonate	Crystalline anhydrous form A1	202825-46-5	✓		✓					
16.	Ticagrelor	Form II	274693-27-5	✓	✓	✓			✓	✓	P

* partnership with Egis

P- pending

DISCLAIMER

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Dapagliflozin (amorphous), Linagliptin, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

We are proud of our **70 years of experience**
in supporting patients' health with **high quality APIs**



HYBRID BUSINESS MODEL

▲ **>70 years of experience in API business**

▲ **Generics and CDMO**

From development to commercial

▲ **European location**


R&D and 2 manufacturing plants

▲ **Agile organisation**

Fast decision making, top execution

▲ **Project management excellence**

▲ **Global market presence**



KEY FACTS



>70
Products

>70
Countries



~455 (R&D ~70, ~16 PHD)
Employees



Regulatory



Full value chain

R&D, production commercial,
supply chain, PMO

MAIN TECHNOLOGIES

BROAD TYPE OF CHEMISTRIES

R&D, Kilo Lab, Pilot, Commercial

- ▲ Highly reactive compounds, organometallic, organophosphorus
- ▲ Powder handling (PSD adjustment) by milling and micronization & Solid-State Chemistry

HIGH POTENT

- ▲ **PDL R&D:** OEB ≤ 6 (OEL $> 10\text{ng/m}^3$)
- ▲ **GMP PP/KL:** OEB ≤ 5 (OEL $> 200\text{ng/m}^3$)
- ▲ **GMP Commercial:** OEB ≤ 6 (OEL $> 10\text{ng/m}^3$)

CRYOGENIC

- ▲ **PP:** Reactor capacity range: 0.1 to 0.5 m³
Operational temperature: down to -80°C
- ▲ **COMMERCIAL:** reactor capacity range: 2.5 to 6.3m³
Total reactors vol: 23.5m³

OLIGONUCLEOTIDES

- ▲ Development and GMP small scale production line by Q3 2024
- ▲ First product validated by Q2 2025

EU-based CDMO and API manufacturer, trusted by customers
and business partners around the world since 70 years



**Polpharma
Pharmaceutical Works**

Pelplinska 19,
83-200 Starogard Gdanski
Poland
+48 58 563 16 00


API CDMO
CDMO@polpharma.com

API GENERICS
API@polpharma.com

LinkedIn
<https://www.linkedin.com/showcase/polpharma-api/>

CUSTOMER SERVICE API
CS.API@polpharma.com

CUSTOMER TECHNICAL SERVICE
techCS.API@polpharma.com

strive for
better 



SAVE THE API PRODUCT LIST